Brainstorm Cell Therapeutics Inc.
BCLI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.03 | 0.05 | -0.56 |
| FCF Yield | -14.10% | -36.27% | -20.41% | -8.09% |
| EV / EBITDA | -4.07 | -3.73 | -2.67 | -4.30 |
| Quality | ||||
| ROIC | 25.11% | 46.95% | 54.32% | 48.34% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 74.56% |
| Cash Conversion Ratio | 0.52 | 1.21 | 0.57 | 0.35 |
| Growth | ||||
| Revenue 3-Year CAGR | 946,796.61% | 946,796.61% | 946,796.61% | 946,796.61% |
| Free Cash Flow Growth | 68.53% | -114.71% | -55.63% | 68.23% |
| Safety | ||||
| Net Debt / EBITDA | -0.16 | 0.10 | -0.04 | -0.17 |
| Interest Coverage | 0.00 | -7.80 | 0.00 | -48.32 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -11,764.04 | 6.68 |